FDA Brief

FDA warning letters

A warning letter is FDA's formal notice that a company broke the law, usually found during an inspection. The company has 15 working days to reply. Letters that go unanswered lead to seizures, import bans or court orders.

6 letters match. Newest first.

  1. Nana Barseghian, M.D.

    FDA warns clinical investigator Nana Barseghian for enrolling high-body-mass-index subjects in drug trials despite protocol exclusion.

    High risk
  2. Mehran Michael Bahrami, M.D.

    FDA warns clinical investigator Dr. Mehran Michael Bahrami over protocol violations and missing records in investigational drug trials.

    High risk
  3. Daniel Fred Goodman, M.D./Goodman Eye Center

    FDA warns Dr. Daniel Fred Goodman/Goodman Eye Center over clinical drug study without required FDA application and missing consent/assent.

    High risk
  4. Smitha C. Reddy, M.D./ACRC Studies, LLC

    FDA warns Dr. Smitha Reddy over clinical trial protocol violations, including wrong drug given and broken blinding.

    High risk
  5. "Daniel C. Tarquinio, D.O./Center for Rare Neurological Diseases

    FDA warns clinical investigator Daniel C. Tarquinio over enrolling ineligible subjects in investigational drug trials.

    High risk
  6. Richard J. Obiso, PhD dba Avila Herbals, LLC

    FDA warns Avila Herbals and investigator over drug trial lacking required FDA application, ethics review, and consent.

    High risk